ClinicalTrials.gg
CompletedNCT02260986CHRONOSUpdated Oct 17, 2017Results posted

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

A Phase 3 interventional study of Dupilumab and Placebo (for Dupilumab) in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 149 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-10-17.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
740
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
3rd of 50
740 · median 75
Started
2014
with 3 others
Phase 3
11 of 50
none open now
Registered
8th of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 3rd largest by enrollment, is one of 4 that started in 2014, is one of 11 in phase 3, and was the 8th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD) compared to placebo administered concomitantly with TCS.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Chronic AD that had been present for at least 3 years before the screening visit;
  2. Documented recent history (within 6 months before the screening visit) of inadequate response to a sufficient course of out-patient treatment with topical AD medication(s).

Key Exclusion Criteria:

  1. Participation in a prior Dupilumab clinical trial;
  2. Important side effects of topical medication (e.g. intolerance to treatment, reactions, significant skin atrophy, systemic effects), as assessed by the investigator or treating physician;
  3. Having used any of the following treatments within 4 weeks before the baseline visit, or any condition that, in the opinion of the investigator, was likely to require such treatment(s) during the first 2 weeks of study treatment:

    1. /immunomodulating drugs (e.g, systemic , cyclosporine, mycophenolate-mofetil, Janus kinase inhibitors, interferon-gamma [IFN-γ], azathioprine, methotrexate, etc.);
    2. Phototherapy for AD;
  4. Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit;
  5. History of (HIV) infection or positive HIV serology at screening;
  6. Positive surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or antibody at the screening visit;
  7. Active or acute infection requiring systemic treatment within 2 weeks before baseline visit;
  8. Known or suspected history of immunosuppression;
  9. Pregnant or breastfeeding women, or planning to become pregnant or breastfeed during the participant's participation in this study.

Note: The eligibility criteria listed above is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial therefore not all inclusion/ exclusion criteria are listed.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
740 participants (actual)

Study arms

  • Experimental
    Placebo qw

    Two subcutaneous injections of Placebo (for Dupilumab) as a loading dose on Day 1 followed by a single injection weekly (qw) from Week 1 to Week 51.

    Drug: Placebo (for Dupilumab) · Other: Topical Corticosteroid (TCS)

  • Experimental
    Dupilumab 300 mg q2w

    Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by placebo (for Dupilumab) alternating with single 300 mg injection of Dupilumab every 2 weeks (q2w) from Week 1 to Week 51. During weeks in which Dupilumab was not administered, participants received placebo.

    Drug: Dupilumab · Drug: Placebo (for Dupilumab) · Other: Topical Corticosteroid (TCS)

  • Experimental
    Dupilumab 300 mg qw

    Two subcutaneous injections of Dupilumab 300 mg (for a total of 600 mg) as a loading dose on Day 1, followed by a single 300 mg injection of Dupilumab qw from Week 1 to Week 51.

    Drug: Dupilumab · Other: Topical Corticosteroid (TCS)

Interventions

  • Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs

    Also known as: REGN668, SAR231893, Dupixent

  • DrugPlacebo (for Dupilumab)

    Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs

  • OtherTopical Corticosteroid (TCS)

    All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16

    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score "0" or "1" and a reduction from baseline of ≥2 points at Week 16 were reported.

    Time frame: Baseline to Week 16

Secondary outcomes

  1. Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16.

    Time frame: Baseline to Week 16

  2. Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 16 were reported.

    Time frame: Baseline to Week 16

  3. Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥3 points from baseline in weekly average of peak daily pruritus NRS score at Week 16 were reported.

    Time frame: Baseline to Week 16

  4. Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 52

    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 52 were reported.

    Time frame: Baseline to Week 52

  5. Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 52

    The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 52.

    Time frame: Baseline to Week 52

  6. Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).

    Time frame: Baseline to Week 16

  7. Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 52 were reported.

    Time frame: Baseline to Week 52

  8. Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥3 points from baseline in weekly average of peak daily pruritus NRS score at Week 52 were reported.

    Time frame: Baseline to Week 52

  9. Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 24

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 24 were reported.

    Time frame: Baseline to Week 24

  10. Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 4

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 4 were reported.

    Time frame: Baseline to Week 4

  11. Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 2

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 2 were reported.

    Time frame: Baseline to Week 2

  12. Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).

    Time frame: Baseline to Week 16

  13. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 16

    The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

    Time frame: Baseline to Week 16

  14. Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 16

    BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined.

    Time frame: Baseline to Week 16

  15. Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 16

    SCORAD was a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Baseline to Week 16

  16. Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 16

    The DLQI was a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score was indicative of a poor QOL.

    Time frame: Baseline to Week 16

  17. Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 16

    The POEM was a 7-item questionnaire that assessed disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]).

    Time frame: Baseline to Week 16

  18. Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 16

    HADS is a fourteen item scale. Seven of the items relate to anxiety and seven items relate to depression. Each item on the questionnaire scored from 0 (minimum score) - 3 (maximum score) and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. Cut-offs for identifying psychiatric distress has been reported as 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression.

    Time frame: Baseline to Week 16

  19. Percent Change From Baseline in Total Global Individual Signs Score (GISS) to Week 16

    Individual components of the AD lesions (erythema, infiltration/ papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0= none, 1= mild, 2= moderate and 3= severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).

    Time frame: Baseline to Week 16

  20. Proportion of Topical Atopic Dermatitis Medication-Free Days Through Week 52

    Proportion of topical AD medication-free days through Week 52 was calculated as the number of days that a participant used neither topical corticosteroid (TCS)/ topical calcineurin inhibitors (TCI) nor system rescue therapy divided by the study days of each period.

    Time frame: Baseline to Week 52

  21. Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 2

    Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).

    Time frame: Baseline to Week 2

  22. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 52

    The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

    Time frame: Baseline to Week 52

  23. Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 52

    BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined.

    Time frame: Baseline to Week 52

  24. Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 52

    SCORAD was a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Baseline to Week 52

  25. Percent Change From Baseline in Global Individual Signs Score (GISS) to Week 52

    Individual components of the AD lesions (erythema, infiltration/ papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0= none, 1= mild, 2= moderate and 3= severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).

    Time frame: Baseline to Week 52

  26. Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 52

    The DLQI was a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score was indicative of a poor QOL.

    Time frame: Baseline to Week 52

  27. Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 52

    The POEM was a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]).

    Time frame: Baseline to Week 52

  28. Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 52

    HADS is a fourteen item scale. Seven of the items relate to anxiety and seven items relate to depression. Each item on the questionnaire is scored from 0 (minimum score) - 3 (maximum score) and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. Cut-offs for identifying psychiatric distress has been reported as 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression.

    Time frame: Baseline to Week 52

  29. Number of Flares Through Week 52

    Atopic dermatitis (AD) flares were defined as worsening of the disease that required escalation/intensification of AD treatment. Number of flares occurred in the participants starting from first dose through Week 52 were reported.

    Time frame: Baseline up to Week 52

  30. Number of Serious Treatment Emergent Adverse Events (TEAEs) Leading to Study Drug Discontinuation Through Week 52

    Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. A Serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.

    Time frame: Baseline up to Week 52

  31. Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Week 52

    Any untoward medical occurrence in a participants who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = "Infection and Infestations" or SOC = "Skin and Subcutaneous Tissue Disorders". Blinded adjudication was performed and finalized by the study medical monitor before database lock.

    Time frame: Baseline up to Week 52

  32. Number of Skin Infection TEAEs (Excluding Herpetic Infections) From Baseline Through Week 52

    Any untoward medical occurrence in a participant who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = "Infection and Infestations" or SOC = "Skin and Subcutaneous Tissue Disorders". Blinded adjudication was performed and finalized by the study medical monitor before database lock.

    Time frame: Baseline up to Week 52

  33. Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52

    Any untoward medical occurrence in a participant who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = "Infection and Infestations" or SOC = "Skin and Subcutaneous Tissue Disorders". Blinded adjudication was performed and finalized by the study medical monitor before database lock.

    Time frame: Baseline up to Week 52

  34. Number of Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52

    Any untoward medical occurrence in a participant who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = "Infection and Infestations" or SOC = "Skin and Subcutaneous Tissue Disorders". Blinded adjudication was performed and finalized by the study medical monitor before database lock.

    Time frame: Baseline up to Week 52

Other outcomes

  1. Change From Baseline in Sinonasal Outcome Test (SNOT-22) Score to Week 16

    The SNOT 22 was a validated measure of health related quality of life in sinonasal disease. It was a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease) (lower scores represent better health related quality of life). The SNOT-22 was administered only to participants with chronic inflammatory conditions of the nasal mucosa and/or paranasal sinuses.

    Time frame: Baseline to Week 16

  2. Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score to Week 16

    ACQ-5 questionnaire was a validated questionnaire comprising of 5 questions for asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath, and wheeze. Participants were asked to rate their asthma symptoms during the previous week on a 7-point scale as 0=no impairment, 6=maximum impairment. ACQ-5 score was the mean of the 5 questions and range between 0 (totally controlled) and 6 (severely uncontrolled) (a higher score indicated lower asthma control). The ACQ-5 questionnaire was administered only to the participants with a medical history of asthma.

    Time frame: Baseline to Week 16

07

Results

Posted Oct 17, 2017

Participant flow

The study was conducted in 14 countries between 16 Sep 2014 and 19 Oct 2016. A total of 957 participants were screened in the study.

Participant flow — Overall Study
MilestonePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Started315106319
Safety population315110315
Completed22593278
Not completed901341
Withdrew: Adverse event24011
Withdrew: Lack of efficacy2730
Withdrew: Protocol violation14516
Withdrew: Car accident001
Withdrew: Withdrawal by subject1749
Withdrew: Incorrect randomization010
Withdrew: Lack of investigation product supply201
Withdrew: Lost to follow-up403
Withdrew: Pregnancy200

Outcome measures

PrimaryPercentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score "0" or "1" and a reduction from baseline of ≥2 points at Week 16 were reported.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16
percentage of participantsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 1612.438.739.2
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 26.3 · 95% CI 16.34 to 36.26Dupilumab 300 mg q2w v Placebo
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 26.8 · 95% CI 20.33 to 33.28Dupilumab 300 mg qw v Placebo
SecondaryPercentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 16.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 16
percentage of participantsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 1623.268.963.9
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 45.7 · 95% CI 35.72 to 55.66Dupilumab 300 mg q2w v Placebo
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 40.8 · 95% CI 33.74 to 47.81Dupilumab 300 mg qw v Placebo
SecondaryPercentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 16 were reported.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16
percentage of participantsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 1619.758.850.8
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 39.1 · 95% CI 28.53 to 49.65Dupilumab 300 mg q2w v Placebo
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 31.1 · 95% CI 23.84 to 38.39Dupilumab 300 mg qw v Placebo
SecondaryPercentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥3 points from baseline in weekly average of peak daily pruritus NRS score at Week 16 were reported.

Time frame:
Baseline to Week 16
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 16
percentage of participantsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 1627.865.762.5
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 37.9 · 95% CI 27.56 to 48.31Dupilumab 300 mg q2w v Placebo
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 34.7 · 95% CI 27.31 to 42.05Dupilumab 300 mg qw v Placebo
SecondaryPercentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 52

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Participants with IGA score of "0" or "1" and a reduction from baseline of ≥2 points at Week 52 were reported.

Time frame:
Baseline to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 52
percentage of participantsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 5212.536.040.0
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 23.5 · 95% CI 12.72 to 34.19Dupilumab 300 mg q2w v Placebo
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 27.5 · 95% CI 20.42 to 34.58Dupilumab 300 mg qw v Placebo
SecondaryPercentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 52

The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD. EASI-75 responders were the participants who achieved ≥75% overall improvement in EASI score from baseline to Week 52.

Time frame:
Baseline to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 52
percentage of participantsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percentage of Participants With Eczema Area and Severity Index-75 (EASI-75) (≥75% Improvement From Baseline) at Week 5221.665.264.1
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 43.6 · 95% CI 32.50 to 54.65Dupilumab 300 mg q2w v Placebo
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 42.5 · 95% CI 34.91 to 50.06Dupilumab 300 mg qw v Placebo
SecondaryPercent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16
percent changePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16-30.3 ± 2.36-56.6 ± 3.95-57.1 ± 2.11
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · ANCOVA · p = <0.0001 (Threshold for significance at 0.025 level.) · Least square (ls) mean difference: -26.2 · 95% CI -35.04 to -17.43Dupilumab 300 mg q2w v Placebo
  • Placebo qw vs Dupilumab 300 mg qw · ANCOVA · p = <0.0001 (Threshold for significance at 0.025 level.) · Ls mean difference: -26.8 · 95% CI -32.83 to -20.73Dupilumab 300 mg qw v Placebo
SecondaryPercentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 52 were reported.

Time frame:
Baseline to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52
percentage of participantsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 5212.951.239.0
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 38.3 · 95% CI 26.96 to 49.66Dupilumab 300 mg q2w v Placebo
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 26.1 · 95% CI 18.76 to 33.45Dupilumab 300 mg qw v Placebo
SecondaryPercentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥3 points from baseline in weekly average of peak daily pruritus NRS score at Week 52 were reported.

Time frame:
Baseline to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 52
percentage of participantsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percentage of Participants With Improvement (Reduction ≥3 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 5215.655.742.9
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 40.1 · 95% CI 28.76 to 51.35Dupilumab 300 mg q2w v Placebo
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 27.3 · 95% CI 19.81 to 34.76Dupilumab 300 mg qw v Placebo
SecondaryPercentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 24

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 24 were reported.

Time frame:
Baseline to Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 24
percentage of participantsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 2416.153.943.7
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 37.9 · 95% CI 27.34 to 48.40Dupilumab 300 mg q2w v Placebo
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 27.7 · 95% CI 20.65 to 34.70Dupilumab 300 mg qw v Placebo
SecondaryPercentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 4

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 4 were reported.

Time frame:
Baseline to Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 4
percentage of participantsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 416.437.327.1
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · Cochran-Mantel-Haenszel · p = <0.0001 (Threshold for significance at 0.025 level.) · Difference in percentages: 20.9 · 95% CI 10.59 to 31.15Dupilumab 300 mg q2w v Placebo
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = 0.0021 (Threshold for significance at 0.025 level.) · Difference in percentages: 10.7 · 95% CI 4.15 to 17.31Dupilumab 300 mg qw v Placebo
SecondaryPercentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 2

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Participants achieving a reduction of ≥4 points from baseline in weekly average of peak daily pruritus NRS score at Week 2 were reported.

Time frame:
Baseline to Week 2
Reported as:
Number · percentage of participants
Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 2
percentage of participantsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percentage of Participants With Improvement (Reduction ≥4 Points) of Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score From Baseline to Week 28.017.613.6
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · Cochran-Mantel-Haenszel · p = 0.0062 (Threshold for significance at 0.025 level.) · Difference in percentages: 9.6 · 95% CI 1.61 to 17.63Dupilumab 300 mg q2w v Placebo
  • Placebo qw vs Dupilumab 300 mg qw · Cochran-Mantel-Haenszel · p = 0.0344 (Threshold for significance at 0.025 level.) · Difference in percentages: 5.5 · 95% CI 0.56 to 10.51Dupilumab 300 mg qw v Placebo
SecondaryChange From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16
units on a scalePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 16-2.36 ± 0.138-4.17 ± 0.207-4.27 ± 0.126
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · ANCOVA · p = <0.0001 (Threshold for significance at 0.025 level.) · Ls mean difference: -1.81 · 95% CI -2.297 to -1.322Dupilumab 300 mg q2w v Placebo
SecondaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 16

The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 16
percent changePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 16-48.4 ± 3.82-80.5 ± 6.34-81.5 ± 5.78
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · ANCOVA · p = <0.0001 (Threshold for significance at 0.025 level.) · Ls mean difference: -32.1 · 95% CI -46.37 to -17.82Dupilumab 300 mg q2w v Placebo
SecondaryChange From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 16

BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Percentage of BSA
Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 16
Percentage of BSAPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 16-22.01 ± 1.158-40.39 ± 1.844-39.58 ± 1.065
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · ANCOVA · p = <0.0001 (Threshold for significance at 0.025 level.) · Ls mean difference: -18.38 · 95% CI -22.583 to -14.187Dupilumab 300 mg q2w v Placebo
SecondaryPercent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 16

SCORAD was a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 16
percent changePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 16-36.2 ± 1.66-63.9 ± 2.52-65.9 ± 1.49
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · ANCOVA · p = <0.0001 (Threshold for significance at 0.025 level.) · Ls mean difference: -27.7 · 95% CI -33.46 to -21.9Dupilumab 300 mg q2w v Placebo
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) to Week 16

The DLQI was a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score was indicative of a poor QOL.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 16
units on a scalePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 16-5.8 ± 0.34-10.0 ± 0.5-10.7 ± 0.31
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · ANCOVA · p = <0.0001 (Threshold for significance at 0.025 level.) · Ls mean difference: -4.2 · 95% CI -5.31 to -3.02Dupilumab 300 mg q2w v Placebo
SecondaryChange From Baseline in Patient Oriented Eczema Measure (POEM) to Week 16

The POEM was a 7-item questionnaire that assessed disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 16
units on a scalePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 16-5.3 ± 0.41-12.7 ± 0.64-12.9 ± 0.37
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · ANCOVA · p = <0.0001 (Threshold for significance at 0.025 level.) · Ls mean difference: -7.4 · 95% CI -8.85 to -5.93Dupilumab 300 mg q2w v Placebo
SecondaryChange From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 16

HADS is a fourteen item scale. Seven of the items relate to anxiety and seven items relate to depression. Each item on the questionnaire scored from 0 (minimum score) - 3 (maximum score) and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. Cut-offs for identifying psychiatric distress has been reported as 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 16
units on a scalePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 16-4.0 ± 0.37-4.9 ± 0.58-5.4 ± 0.35
Statistical analysis
  • Placebo qw vs Dupilumab 300 mg q2w · ANCOVA · p = 0.1596 (Threshold for significance at 0.025 level.) · Ls mean difference: -1.00 · 95% CI -2.27 to 0.37Dupilumab 300 mg q2w v Placebo
SecondaryPercent Change From Baseline in Total Global Individual Signs Score (GISS) to Week 16

Individual components of the AD lesions (erythema, infiltration/ papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0= none, 1= mild, 2= moderate and 3= severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Global Individual Signs Score (GISS) to Week 16
percent changePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percent Change From Baseline in Total Global Individual Signs Score (GISS) to Week 16-33.3 ± 1.89-55.4 ± 2.69-59.3 ± 1.64
SecondaryProportion of Topical Atopic Dermatitis Medication-Free Days Through Week 52

Proportion of topical AD medication-free days through Week 52 was calculated as the number of days that a participant used neither topical corticosteroid (TCS)/ topical calcineurin inhibitors (TCI) nor system rescue therapy divided by the study days of each period.

Time frame:
Baseline to Week 52
Reported as:
Mean · days
Proportion of Topical Atopic Dermatitis Medication-Free Days Through Week 52
daysPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Proportion of Topical Atopic Dermatitis Medication-Free Days Through Week 5210.5 ± 23.6816.6 ± 30.0822.5 ± 33.69
SecondaryPercent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 2

Pruritus NRS was an assessment tool that was used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]).

Time frame:
Baseline to Week 2
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 2
percent changePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percent Change From Baseline in Weekly Average of Peak Daily Pruritus Numerical Rating Scale (NRS) Score to Week 2-19.7 ± 1.58-27.3 ± 2.67-25.7 ± 1.57
SecondaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 52

The EASI score was used to measure the severity and extent of AD and measured erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 (minimum) to 72 (maximum) points, with the higher scores reflecting the worse severity of AD.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 52
percent changePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score to Week 52-60.9 ± 4.29-84.9 ± 6.73-87.8 ± 6.19
SecondaryChange From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 52

BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Percentage of BSA
Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 52
Percentage of BSAPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Change From Baseline in Percent Body Surface Area (BSA) Affected by Atopic Dermatitis to Week 52-29.41 ± 1.443-43.75 ± 1.874-43.67 ± 1.143
SecondaryPercent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 52

SCORAD was a clinical tool for assessing the severity of AD developed by the European Task Force on Atopic Dermatitis (Severity scoring of atopic dermatitis: the SCORAD index). Consensus Report of the European Task Force on Atopic Dermatitis. Dermatology (Basel) 186 (1): 23-31. 1993. Extent and intensity of eczema as well as subjective signs (insomnia, etc.) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 52
percent changePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Score to Week 52-47.3 ± 2.18-69.7 ± 3.06-70.4 ± 1.72
SecondaryPercent Change From Baseline in Global Individual Signs Score (GISS) to Week 52

Individual components of the AD lesions (erythema, infiltration/ papulation, excoriations, and lichenification) were rated globally (each assessed for the whole body, not by anatomical region) on a 4-point scale (0= none, 1= mild, 2= moderate and 3= severe) using the EASI severity grading criteria. Total score ranges from 0 (absent disease) to 12 (severe disease).

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Global Individual Signs Score (GISS) to Week 52
percent changePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percent Change From Baseline in Global Individual Signs Score (GISS) to Week 52-40.8 ± 2.72-62.8 ± 3.35-64.4 ± 2.13
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) to Week 52

The DLQI was a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life (QOL). The 10 questions assessed QOL over the past week, with an overall scoring of 0 (absent disease) to 30 (severe disease); a high score was indicative of a poor QOL.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 52
units on a scalePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Change From Baseline in Dermatology Life Quality Index (DLQI) to Week 52-7.2 ± 0.4-11.4 ± 0.57-11.1 ± 0.36
SecondaryChange From Baseline in Patient Oriented Eczema Measure (POEM) to Week 52

The POEM was a 7-item questionnaire that assesses disease symptoms (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) with a scoring system of 0 (absent disease) to 28 (severe disease) (high score indicative of poor quality of life \[QOL\]).

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 52
units on a scalePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Change From Baseline in Patient Oriented Eczema Measure (POEM) to Week 52-7.0 ± 0.57-14.2 ± 0.78-13.2 ± 0.45
SecondaryChange From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 52

HADS is a fourteen item scale. Seven of the items relate to anxiety and seven items relate to depression. Each item on the questionnaire is scored from 0 (minimum score) - 3 (maximum score) and this means that a person can score between 0 (no symptoms) and 21 (severe symptoms) for either anxiety or depression. Cut-offs for identifying psychiatric distress has been reported as 7 to 8 for possible presence, 10 to 11 for probable presence, and 14 to 15 for severe anxiety or depression.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 52
units on a scalePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Change From Baseline in Hospital Anxiety Depression Scale (HADS) to Week 52-3.8 ± 0.47-5.5 ± 0.71-5.9 ± 0.42
SecondaryNumber of Flares Through Week 52

Atopic dermatitis (AD) flares were defined as worsening of the disease that required escalation/intensification of AD treatment. Number of flares occurred in the participants starting from first dose through Week 52 were reported.

Time frame:
Baseline up to Week 52
Reported as:
Number · flares
Number of Flares Through Week 52
flaresPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Number of Flares Through Week 522162051
SecondaryNumber of Serious Treatment Emergent Adverse Events (TEAEs) Leading to Study Drug Discontinuation Through Week 52

Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an AE without regard to possibility of causal relationship with this treatment. A Serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs.

Time frame:
Baseline up to Week 52
Reported as:
Number · events
Number of Serious Treatment Emergent Adverse Events (TEAEs) Leading to Study Drug Discontinuation Through Week 52
eventsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Number of Serious Treatment Emergent Adverse Events (TEAEs) Leading to Study Drug Discontinuation Through Week 5228210
SecondaryPercentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Week 52

Any untoward medical occurrence in a participants who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = "Infection and Infestations" or SOC = "Skin and Subcutaneous Tissue Disorders". Blinded adjudication was performed and finalized by the study medical monitor before database lock.

Time frame:
Baseline up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Week 52
percentage of participantsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) From Baseline Through Week 5217.810.98.3
SecondaryNumber of Skin Infection TEAEs (Excluding Herpetic Infections) From Baseline Through Week 52

Any untoward medical occurrence in a participant who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = "Infection and Infestations" or SOC = "Skin and Subcutaneous Tissue Disorders". Blinded adjudication was performed and finalized by the study medical monitor before database lock.

Time frame:
Baseline up to Week 52
Reported as:
Number · events
Number of Skin Infection TEAEs (Excluding Herpetic Infections) From Baseline Through Week 52
eventsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Number of Skin Infection TEAEs (Excluding Herpetic Infections) From Baseline Through Week 52801529
SecondaryPercentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52

Any untoward medical occurrence in a participant who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = "Infection and Infestations" or SOC = "Skin and Subcutaneous Tissue Disorders". Blinded adjudication was performed and finalized by the study medical monitor before database lock.

Time frame:
Baseline up to Week 52
Reported as:
Number · percentage of participants
Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52
percentage of participantsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Percentage of Participants With Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 529.55.53.8
SecondaryNumber of Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52

Any untoward medical occurrence in a participant who received IMP was considered an AE without regard to possibility of causal relationship with this treatment. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (time from the first dose of study drug up to end of treatment at Week 52). Any TEAE included participants with both serious and non-serious AEs. Skin infection TEAEs were identified based on blinded adjudication of all reported TEAEs under the 2 primary System Organ Classes (SOC): SOC = "Infection and Infestations" or SOC = "Skin and Subcutaneous Tissue Disorders". Blinded adjudication was performed and finalized by the study medical monitor before database lock.

Time frame:
Baseline up to Week 52
Reported as:
Number · events
Number of Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 52
eventsPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Number of Skin Infection Treatment Emergent Adverse Events (TEAEs) (Excluding Herpetic Infections) Requiring Systemic Treatment From Baseline Through Week 5244713
Other pre-specifiedChange From Baseline in Sinonasal Outcome Test (SNOT-22) Score to Week 16

The SNOT 22 was a validated measure of health related quality of life in sinonasal disease. It was a 22 item questionnaire with each item assigned a score ranging from 0-5. The total score may range from 0 (no disease) -110 (worst disease) (lower scores represent better health related quality of life). The SNOT-22 was administered only to participants with chronic inflammatory conditions of the nasal mucosa and/or paranasal sinuses.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Sinonasal Outcome Test (SNOT-22) Score to Week 16
units on a scalePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Change From Baseline in Sinonasal Outcome Test (SNOT-22) Score to Week 16-4.77 ± 1.903-6.38 ± 2.445-10.39 ± 1.63
Other pre-specifiedChange From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score to Week 16

ACQ-5 questionnaire was a validated questionnaire comprising of 5 questions for asthma symptoms: woken at night by symptoms, wake in the mornings with symptoms, limitation of daily activities, shortness of breath, and wheeze. Participants were asked to rate their asthma symptoms during the previous week on a 7-point scale as 0=no impairment, 6=maximum impairment. ACQ-5 score was the mean of the 5 questions and range between 0 (totally controlled) and 6 (severely uncontrolled) (a higher score indicated lower asthma control). The ACQ-5 questionnaire was administered only to the participants with a medical history of asthma.

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · units on a scale
Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score to Week 16
units on a scalePlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score to Week 16-0.12 ± 0.082-0.19 ± 0.113-0.36 ± 0.068

Adverse events

Collected over Time-frame was 'On treatment (Week 52) period' defined time from administration of first dose of study drug to study completion date of Week 52 visit (365 days starting from first dose of study drug if the date of Week 52 visit was unavailable).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo qw0/315 (0%)20/315 (6.3%)216/315 (68.6%)
Dupilumab 300 mg q2w0/110 (0%)4/110 (3.6%)74/110 (67.3%)
Dupilumab 300 mg qw1/315 (0.3%)12/315 (3.8%)228/315 (72.4%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Superinfection bacterialInfections and infestations0/3151/1100/315
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3151/1101/315
Cerebral infarctionNervous system disorders0/3151/1100/315
AnxietyPsychiatric disorders0/3151/1100/315
Dermatitis atopicSkin and subcutaneous tissue disorders1/3151/1101/315
Acute myocardial infarctionCardiac disorders1/3150/1100/315
CataractEye disorders1/3150/1100/315
Cystoid macular oedemaEye disorders0/3150/1101/315
GlaucomaEye disorders1/3150/1100/315
PancreatitisGastrointestinal disorders1/3150/1100/315
Most frequent other events
Showing 10 of 12
Most frequent other events
EventPlacebo qwDupilumab 300 mg q2wDupilumab 300 mg qw
Dermatitis atopicSkin and subcutaneous tissue disorders161/31540/11091/315
NasopharyngitisInfections and infestations62/31526/11063/315
Injection site reactionGeneral disorders24/31516/11060/315
Conjunctivitis allergicEye disorders19/31513/11054/315
Upper respiratory tract infectionInfections and infestations34/31511/11046/315
HeadacheNervous system disorders19/3155/11024/315
AsthmaRespiratory, thoracic and mediastinal disorders19/3155/1107/315
SinusitisInfections and infestations9/3152/11018/315
BlepharitisEye disorders3/3156/11011/315
InfluenzaInfections and infestations17/3154/1109/315

Baseline characteristics

Baseline population included all randomized participants.

Age, Continuous
Age, Continuous(years)Placebo qwDupilumab 300 mg q2wDupilumab 300 mg qwTotal
Mean36.6 ± 13.0139.6 ± 13.9836.9 ± 13.6737.1 ± 13.46
Sex: Female, Male
Sex: Female, Male(Participants)Placebo qwDupilumab 300 mg q2wDupilumab 300 mg qwTotal
Female12244128294
Male19362191446
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo qwDupilumab 300 mg q2wDupilumab 300 mg qwTotal
Hispanic or Latino102517
Not Hispanic or Latino299103309711
Unknown or Not Reported61512
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo qwDupilumab 300 mg q2wDupilumab 300 mg qwTotal
American Indian or Alaska Native0000
Asian832989201
Native Hawaiian or Other Pacific Islander0000
Black or African American1921334
White20874208490
More than one race0000
Unknown or Not Reported51915
Region of Enrollment
Region of Enrollment(participants)Placebo qwDupilumab 300 mg q2wDupilumab 300 mg qwTotal
Romania2024
Hungary1151127
United States611959139
Japan541647117
United Kingdom1741536
Spain42410
New Zealand1135
Canada471751115
Czech Republic77620
Netherlands1771943
Korea, Republic of841426
Poland631764144
Italy51713
Australia1861741
Eczema Area and Severity Index (EASI) Score
Eczema Area and Severity Index (EASI) Score(units on a scale)Placebo qwDupilumab 300 mg q2wDupilumab 300 mg qwTotal
Mean32.6 ± 12.9333.6 ± 13.3032.1 ± 12.7632.5 ± 12.90
Investigator Global Assessment (IGA) Score
Investigator Global Assessment (IGA) Score(units on a scale)Placebo qwDupilumab 300 mg q2wDupilumab 300 mg qwTotal
Mean3.5 ± 0.503.5 ± 0.503.5 ± 0.503.5 ± 0.50
Weekly Peak Averaged Pruritus Numeric Rating Scale (NRS)
Weekly Peak Averaged Pruritus Numeric Rating Scale (NRS)(units on a scale)Placebo qwDupilumab 300 mg q2wDupilumab 300 mg qwTotal
Mean7.3 ± 1.847.4 ± 1.667.1 ± 1.907.3 ± 1.84

6 further baseline measures are reported on the registry.

08

Study locations

149 sites
  • Phoenix, Arizona, United States
  • Hot Springs, Arkansas, United States
  • Little Rock, Arkansas, United States
  • Encinitas, California, United States
  • Oceanside, California, United States
  • Palmdale, California, United States
  • San Diego, California, United States
  • New Haven, Connecticut, United States
  • Trumbull, Connecticut, United States
  • Edgewater, Florida, United States
  • Lake Worth, Florida, United States
  • Miami Lakes, Florida, United States
  • Orlando, Florida, United States
  • Tampa, Florida, United States
  • Alpharetta, Georgia, United States
  • Columbus, Georgia, United States
  • Savannah, Georgia, United States
  • West Dundee, Illinois, United States
  • Carmel, Indiana, United States
  • New Albany, Indiana, United States
  • Rockville, Maryland, United States
  • Ann Arbor, Michigan, United States
  • Bay City, Michigan, United States
  • Edina, Minnesota, United States
  • Fridley, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Omaha, Nebraska, United States
  • Henderson, Nevada, United States
  • Verona, New Jersey, United States
  • Albuquerque, New Mexico, United States
  • Corning, New York, United States
  • New York, New York, United States
  • Smithtown, New York, United States
  • Stony Brook, New York, United States
  • Cincinnati, Ohio, United States
  • Norman, Oklahoma, United States
  • Oklahoma City, Oklahoma, United States
  • Lake Oswego, Oregon, United States
  • Portland, Oregon, United States
  • Exton, Pennsylvania, United States
  • Hazleton, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Austin, Texas, United States
  • Dallas, Texas, United States
  • West Jordan, Utah, United States
  • South Burlington, Vermont, United States
  • Henrico, Virginia, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Spokane, Washington, United States
  • Phillip, Australian Capital Territory, Australia
  • Kogarah, New South Wales, Australia
  • Benowa, Queensland, Australia
  • Dulwich, Queensland, Australia
  • Hectorville, South Australia, Australia
  • Carlton, Victoria, Australia
  • Surrey, British Columbia, Canada
  • Vancouver, British Columbia, Canada
  • Ajax, Ontario, Canada
  • Barrie, Ontario, Canada
  • Hamilton, Ontario, Canada
  • Markham, Ontario, Canada
  • North Bay, Ontario, Canada
  • Oakville, Ontario, Canada
  • Ottawa, Ontario, Canada
  • Peterborough, Ontario, Canada
  • Richmond Hill, Ontario, Canada
  • Toronto, Ontario, Canada
  • Waterloo, Ontario, Canada
  • Windsor, Ontario, Canada
  • Drummondville, Quebec, Canada
  • Quebec, Canada
  • Hradec Kralove, Czechia
  • Nachod, Czechia
  • Praha 10, Czechia
  • Praha 5, Czechia
  • Svitavy, Czechia
  • Usti nad Labem, Czechia
  • Oroshaza, Békés, Hungary
  • Szolnok, Jász-Nagykun-Szolnok, Hungary
  • Veszprem, Veszprém, Hungary
  • Budapest, Hungary
  • Ancona, Italy
  • Bologna, Italy
  • Brescia, Italy
  • Novara, Italy
  • Pavia, Italy
  • Perugia, Italy
  • Roma, Italy
  • Kitakyushu, Fukuoka, Japan
  • Amagasaki, Hyôgo, Japan
  • Yokohama, Kanagawa, Japan
  • Kamimashiki-gun, Kumamoto, Japan
  • Saitama-shi, Saitama, Japan
  • Yaizu, Shizuoka, Japan
  • Koto-ku, Tokyo, Japan
  • Setagaya-ku, Tokyo, Japan
  • Adachi-ku, Tôkyô, Japan
  • Chiyoda-ku, Tôkyô, Japan
  • Nakano-ku, Tôkyô, Japan

Showing the first 100 of 149 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Wechsler ME, Klion AD, Paggiaro P, Nair P, Staumont-Salle D, Radwan A, Johnson RR, Kapoor U, Khokhar FA, Daizadeh N, Chen Z, Laws E, Ortiz B, Jacob-Nara JA, Mannent LP, Rowe PJ, Deniz Y. Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. J Allergy Clin Immunol Pract. 2022 Oct;10(10):2695-2709. doi: 10.1016/j.jaip.2022.05.019. Epub 2022 May 28. PubMed 35636689 ↗
  • Blauvelt A, de Bruin-Weller M, Simpson EL, Chen Z, Ardeleanu M, Rossi AB. Consistency of Response to Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis Over 1 Year. Dermatol Ther (Heidelb). 2022 Jan;12(1):9-13. doi: 10.1007/s13555-021-00657-y. Epub 2022 Jan 7. PubMed 34994968 ↗
  • Blauvelt A, de Bruin-Weller M, Simpson EL, Chen Z, Zhang A, Shumel B. Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks. Dermatol Ther (Heidelb). 2022 Jan;12(1):223-231. doi: 10.1007/s13555-021-00638-1. Epub 2021 Nov 22. PubMed 34806137 ↗
  • Griffiths C, de Bruin-Weller M, Deleuran M, Fargnoli MC, Staumont-Salle D, Hong CH, Sanchez-Carazo J, Foley P, Seo SJ, Msihid J, Chen Z, Cyr SL, Rossi AB. Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials. Dermatol Ther (Heidelb). 2021 Aug;11(4):1357-1372. doi: 10.1007/s13555-021-00558-0. Epub 2021 Jun 18. PubMed 34142350 ↗
  • Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, Amin N, Ardeleanu M, Radin A, Shumel B, Ruddy M, Patel N, Pirozzi G, Mannent L, Graham NMH. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Exp Allergy. 2021 Jul;51(7):915-931. doi: 10.1111/cea.13954. Epub 2021 Jun 26. PubMed 34037993 ↗
  • Wu JJ, Spelman L, Tan JL, Etoh T, Zhang H, Shumel B, Rossi AB. Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial. Dermatol Ther (Heidelb). 2021 Apr;11(2):327-330. doi: 10.1007/s13555-021-00487-y. Epub 2021 Jan 28. No abstract available. PubMed 33511576 ↗
  • Boguniewicz M, Beck LA, Sher L, Guttman-Yassky E, Thaci D, Blauvelt A, Worm M, Corren J, Soong W, Lio P, Rossi AB, Lu Y, Chao J, Eckert L, Gadkari A, Hultsch T, Ruddy M, Mannent LP, Graham NMH, Pirozzi G, Chen Z, Ardeleanu M. Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis. J Allergy Clin Immunol Pract. 2021 Mar;9(3):1212-1223.e6. doi: 10.1016/j.jaip.2020.12.059. Epub 2021 Jan 13. PubMed 33453450 ↗
  • Silverberg JI, Simpson EL, Guttman-Yassky E, Cork MJ, de Bruin-Weller M, Yosipovitch G, Eckert L, Chen Z, Ardeleanu M, Shumel B, Hultsch T, Rossi AB, Hamilton JD, Orengo JM, Ruddy M, Graham NMH, Pirozzi G, Gadkari A. Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials. Dermatitis. 2021 Oct 1;32(1S):S81-S91. doi: 10.1097/DER.0000000000000698. PubMed 33165005 ↗
  • Weyne J, Blauvelt A, de Bruin-Weller M, Prens E, Asbell P, Sierka D, Chen Z, Shumel B. Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial. Dermatol Ther (Heidelb). 2020 Dec;10(6):1415-1421. doi: 10.1007/s13555-020-00456-x. Epub 2020 Oct 12. PubMed 33047298 ↗
  • Katoh N, Kataoka Y, Saeki H, Hide M, Kabashima K, Etoh T, Igarashi A, Imafuku S, Kawashima M, Ohtsuki M, Fujita H, Arima K, Takagi H, Chen Z, Shumel B, Ardeleanu M. Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials. Br J Dermatol. 2020 Jul;183(1):39-51. doi: 10.1111/bjd.18565. Epub 2019 Nov 28. PubMed 31564057 ↗
  • Alexis AF, Rendon M, Silverberg JI, Pariser DM, Lockshin B, Griffiths CE, Weisman J, Wollenberg A, Chen Z, Davis JD, Li M, Eckert L, Gadkari A, Shumel B, Rossi AB, Graham NM, Ardeleanu M. Efficacy of Dupilumab in Different Racial Subgroups of Adults With Moderate-to-Severe Atopic Dermatitis in Three Randomized, Placebo-Controlled Phase 3 Trials. J Drugs Dermatol. 2019 Aug 1;18(8):804-813. PubMed 31424712 ↗
  • Wollenberg A, Beck LA, Blauvelt A, Simpson EL, Chen Z, Chen Q, Shumel B, Khokhar FA, Hultsch T, Rizova E, Rossi AB, Graham NMH, Pirozzi G, Lu Y, Ardeleanu M. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020 May;182(5):1120-1135. doi: 10.1111/bjd.18434. Epub 2019 Dec 1. PubMed 31407311 ↗
  • Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemeny L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4. PubMed 28478972 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Aug 2015 and a completion of Oct 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2017, 2 years 2 months after primary completion. A results delay was requested in Feb 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2014
First posted
Oct 9, 2014
Start
Sep 2014
Primary completionActual
Aug 2015
CompletionActual
Oct 2016
Results delay requested
Feb 7, 2017
Results first posted
Oct 17, 2017
Last update
Oct 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02260986
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Oct 9, 2014
Start date
Sep 2014
Primary completion
Aug 2015
Completion
Oct 2016
Results posted
Oct 17, 2017
Last update
Oct 17, 2017

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion